Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS

Beneficial Ownership Report · SCHEDULE 13D/A

LIFECORE BIOMEDICAL, INC. \DE\

LFCRNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Sep 28, 2026Accepted Sep 28, 2026, 5:41 PM EDTFiling CIK 1560207Accession 0000921895-26-002661
Share

Structured filing — SCHEDULE 13D/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
LIFECORE BIOMEDICAL, INC. \DE\
Company CIK
0001005286
Street
3515 LYMAN BOULEVARD
City
CHASKA
State / country code
MN
Postal code
55318

Statement details

Amendment number
11
Security class
Common Stock, par value $0.001 per share
Event date
09/27/2026
Previously filed indication
false

Authorized notification person 1

Name
CHRISTOPHER S. KIPER
Phone
424-253-1773
Street
LEGION PARTNERS ASSET MANAGEMENT, LLC
Street (continued)
12121 Wilshire Blvd, Suite 1240
City
Los Angeles
State / country code
CA
Postal code
90025

Authorized notification person 2

Name
RYAN NEBEL
Phone
212-451-2300
Street
OLSHAN FROME WOLOSKY LLP
Street (continued)
1325 Avenue of the Americas
City
New York
State / country code
NY
Postal code
10019

Reporting person 1

Name
Legion Partners, L.P. I
Reporting person CIK
0001595909
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
PN
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
6,376,738.00
Percent of class
15.9
Sole voting power
0.00
Shared voting power
6,376,738.00
Sole dispositive power
0.00
Shared dispositive power
6,376,738.00
Aggregate excludes certain shares
N

Reporting person 2

Name
Legion Partners, L.P. II
Reporting person CIK
0001618783
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
PN
Source of funds code
WC
Legal proceedings indication
N
Aggregate amount owned
537,406.00
Percent of class
1.4
Sole voting power
0.00
Shared voting power
537,406.00
Sole dispositive power
0.00
Shared dispositive power
537,406.00
Aggregate excludes certain shares
N

Reporting person 3

Name
Legion Partners, LLC
Reporting person CIK
0001682390
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
OO
Source of funds code
AF
Legal proceedings indication
N
Aggregate amount owned
6,914,144.00
Percent of class
17.1
Sole voting power
0.00
Shared voting power
6,914,144.00
Sole dispositive power
0.00
Shared dispositive power
6,914,144.00
Aggregate excludes certain shares
N

Reporting person 4

Name
Legion Partners Asset Management, LLC
Reporting person CIK
0001560207
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
IA · OO
Source of funds code
AF · OO
Legal proceedings indication
N
Aggregate amount owned
6,991,719.00
Percent of class
17.3
Sole voting power
0.00
Shared voting power
6,991,719.00
Sole dispositive power
0.00
Shared dispositive power
6,991,719.00
Aggregate excludes certain shares
N

Reporting person 5

Name
Legion Partners Holdings, LLC
Reporting person CIK
0001682389
No reporting person CIK indication
N
Citizenship / organization
DE
Reporting person type
OO
Source of funds code
AF · WC · OO
Legal proceedings indication
N
Aggregate amount owned
6,991,919.00
Percent of class
17.3
Sole voting power
0.00
Shared voting power
6,991,919.00
Sole dispositive power
0.00
Shared dispositive power
6,991,919.00
Aggregate excludes certain shares
N

Reporting person 6

Name
Kiper Christopher S
Reporting person CIK
0001432744
No reporting person CIK indication
N
Citizenship / organization
X1
Reporting person type
IN
Source of funds code
AF · OO
Legal proceedings indication
N
Aggregate amount owned
6,991,919.00
Percent of class
17.3
Sole voting power
0.00
Shared voting power
6,991,919.00
Sole dispositive power
0.00
Shared dispositive power
6,991,919.00
Aggregate excludes certain shares
N

Reporting person 7

Name
White Raymond T.
Reporting person CIK
0001682494
No reporting person CIK indication
N
Citizenship / organization
X1
Reporting person type
IN
Source of funds code
AF · OO
Legal proceedings indication
N
Aggregate amount owned
6,991,919.00
Percent of class
17.3
Sole voting power
0.00
Shared voting power
6,991,919.00
Sole dispositive power
0.00
Shared dispositive power
6,991,919.00
Aggregate excludes certain shares
N

Item 1

Issuer

LIFECORE BIOMEDICAL, INC. \DE\

Security title

Common Stock, par value $0.001 per share

Principal address

Item 3

Source of funds

Item 3 is hereby amended and restated to read as follows: The Shares purchased by each of Legion Partners I, Legion Partners II and Legion Partners Holdings were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 4,084,268 Shares owned directly by Legion Partners I is approximately $33,506,562, including brokerage commissions. The aggregate purchase price of the 319,286 Shares owned directly by Legion Partners II is approximately $2,348,906, including brokerage commissions. The aggregate purchase price of the 200 Shares owned directly by Legion Partners Holdings is approximately $2,082, including brokerage commissions. As detailed in Item 4 of Amendment No. 6, which information is incorporated herein by reference, the Series A Preferred Stock (as defined therein) purchased by Legion Partners I and Legion Partners II are converted into Shares at any time by Legion Partners I and Legion Partners II, which Shares are treated as beneficially owned for purposes of this Schedule 13D. The shares of Series A Preferred Stock purchased by each of Legion Partners I and Legion Partners II were purchased directly from the Issuer with working capital pursuant to the terms of the Purchase Agreement (as defined therein). The aggregate purchase price of the 11,414 shares of Series A Preferred Stock owned directly by Legion Partners I is approximately $11,414,000. Approximately 3,563 Shares of Series A Preferred Stock owned directly by Legion Partners I were received as dividends. The aggregate purchase price of the 1,086 shares of Series A Preferred Stock owned directly by Legion Partners II is approximately $1,086,000. Approximately 339 Shares of Series A Preferred Stock owned directly by Legion Partners II were received as dividends. In connection with the appointment of Christopher S. Kiper to the Board of Directors of the Issuer (the "Board"), as further described in Item 4 to Amendment No. 6, Mr. Kiper has been awarded certain restricted stock units ("RSUs") in connection with his service as a director of the Issuer, including (i) 5,906 RSUs awarded on January 9, 2023 which vested on the first anniversary of the grant date and were automatically settled in Shares, (ii) 3,981 RSUs awarded on February 1, 2023 that vested on the first anniversary of the grant date and were automatically settled in Shares, (iii) 18,182 RSUs awarded on June 1, 2023 that vested on the first anniversary of the grant date and were automatically settled in Shares, (iv) 30,000 RSUs awarded on July 8, 2024 that vested on the first anniversary of the grant date and were automatically settled in Shares, (v) 19,506 RSUs awarded on July 15, 2025 that vested on the first anniversary of the grant date and were automatically settled in Shares, and (vi) 25,907 RSUs awarded on June 4, 2026 that vest on the earlier of June 4, 2027 or the date of the annual meeting of stockholders first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). Because Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and the Reporting Persons, he does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position. As a result, when the Issuer delivered such RSUs to Mr. Kiper, Legion Partners Asset Management was entitled to receive all of the economic interests in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position, for no consideration.

Item 4

Purpose of transaction

Item 4 is hereby amended to add the following: On September 27, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lifecore Inc., a Delaware corporation ("Parent"), and Hazel Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of Parent ("Merger Sub"). The Merger Agreement provides that, among other things, on the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. Under the terms of the Merger Agreement, each Share issued and outstanding immediately prior to the date and time that the Merger becomes effective (the "Effective Time"), excluding any Excluded Shares (as defined below), will receive $6.28 per Share in cash plus one (1) contingent value right per share (each, a "CVR") (collectively, the "Common Stock Merger Consideration"). Excluded Shares include Shares or Series A Preferred Stock held by the Issuer, Parent or Merger Sub, and Dissenting Shares. At the Effective Time, each share of the Series A Preferred Stock issued and outstanding immediately prior to the Effective Time, excluding any Excluded Shares, will be canceled and cease to exist and be converted into the right to receive an amount in cash per share of Series A Preferred Stock equal to the "Conversion Amount" as defined in Section 3 of the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock plus one (1) CVR per Share into which the Series A Preferred Stock is convertible as of immediately prior to the Effective Time under the Certificate of Designations. Completion of the Merger is subject to customary closing conditions, including, (i) the adoption of the Merger Agreement by Issuer stockholders at a special meeting (the "Issuer Required Vote"), (ii) the expiration or termination of the applicable waiting period (or any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), (iii) the other required governmental consents, registrations, notice or approvals will have been made or obtained, and (iv) the absence of any legal restraint that prohibits, or makes illegal the consummation of the Merger. On September 27, 2026, in connection with the execution of the Merger Agreement, the Reporting Persons entered into a voting and support agreement (the "Voting Agreement") with the Issuer and Parent. Pursuant to the Voting Agreement, the Reporting Persons generally agreed not to transfer any Shares owned as of the date of the agreement or acquired after the date of the agreement (the "Covered Shares"). In addition, the Reporting Persons agreed that, at any meeting of the Issuer's stockholders, they will vote their Covered Shares (a) in favor of the approval and adoption of the Merger Agreement and approval of the Merger and the other transactions contemplated by the Merger Agreement, (b) in favor of any proposal to adjourn or postpone the meeting to a later date if there are not sufficient votes present for there to be a quorum or for the approval and adoption of the Merger Agreement, and (c) against (i) any action, proposal, transaction, or agreement that would reasonably be expected to result in any condition to the Merger Agreement not being satisfied prior to the termination of the Merger Agreement or (ii) any Acquisition Proposal (as defined in the Merger Agreement) or agreement, transaction, or other matter that is intended to or would reasonably be expected to impede, interfere, or materially and adversely affect the consummation of the Merger and the other transactions contemplated by the Merger Agreement. The Voting Agreement will continue until the earliest to occur of (a) the time that the Company Required Vote (as defined in the Merger Agreement) has been obtained, (b) the Effective Time, (c) such date and time as the Merger Agreement shall be validly terminated or (d) upon a Company Adverse Change Recommendation (as defined in the Merger Agreement) effected by the Issuer's Board in accordance with the Merger Agreement. The foregoing description of the Voting Agreement does not purport to be complete and is qualified in its entirety by reference to the Voting Agreement, which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 5

Number of shares

Item 5(b) is hereby amended and restated to read as follows: A. Legion Partners I 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 6,376,738 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 6,376,738 B. Legion Partners II 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 537,406 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 537,406 C. Legion Partners, LLC 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 6,914,144 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 6,914,144 D. Legion Partners Asset Management 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 6,991,719 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 6,991,719 E. Legion Partners Holdings 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 6,991,919 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 6,991,919 F. Messrs. Kiper and White 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 6,991,919 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 6,991,919

Transactions

Item 5(c) is hereby amended and restated to read as follows: None of the Reporting Persons have entered into any transactions in the securities of the Issuer during the past 60 days.

Percentage of class

Item 5(a) is hereby amended and restated to read as follows: The aggregate percentage of Shares reported owned by each person named herein is based on a denominator that is the sum of: (i) 37,905,846 Shares outstanding, which is the total number of Shares outstanding as of September 25, 2026, as set forth in Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the SEC on September 28, 2026, and (ii) the Shares underlying the Series A Preferred Stock that can be converted by the Reporting Persons, as applicable. A. Legion Partners I As of the date hereof, Legion Partners I beneficially owned 6,376,738 Shares, including 2,292,470 Shares issuable upon conversion of certain shares of Series A Preferred Stock that are immediately convertible. Percentage: Approximately 15.9% B. Legion Partners II As of the date hereof, Legion Partners II beneficially owned 537,406 Shares, including 218,120 Shares issuable upon conversion of certain shares of Series A Preferred Stock that are immediately convertible. Percentage: Approximately 1.4% C. Legion Partners, LLC As the general partner of each of Legion Partners I and Legion Partners II, Legion Partners, LLC may be deemed the beneficial owner of the (i) 6,376,738 Shares beneficially owned by Legion Partners I and (ii) 537,406 Shares beneficially owned by Legion Partners II. Percentage: Approximately 17.1% D. Legion Partners Asset Management As of the date hereof, Legion Partners Asset Management may be deemed to beneficially own the 77,575 Shares that were granted to Mr. Kiper by the Issuer in his capacity as a director of the Issuer, as further explained in Item 3. As the investment advisor of each of Legion Partners I and Legion Partners II, Legion Partners Asset Management may also be deemed the beneficial owner of the (i) 6,376,738 Shares beneficially owned by Legion Partners I and (ii) 537,406 Shares beneficially owned by Legion Partners II. Percentage: Approximately 17.3% E. Legion Partners Holdings As of the date hereof, Legion Partners Holdings directly beneficially owned 200 Shares. As the sole member of Legion Partners Asset Management and the sole member of Legion Partners, LLC, Legion Partners Holdings may also be deemed the beneficial owner of the (i) 6,376,738 Shares beneficially owned by Legion Partners I, (ii) 537,406 Shares beneficially owned by Legion Partners II and (iii) 77,575 Shares that were granted to Mr. Kiper by the Issuer in his capacity as a director of the Issuer. Percentage: Approximately 17.3% F. Messrs. Kiper and White Each of Messrs. Kiper and White, as a managing director of Legion Partners Asset Management and a managing member of Legion Partners Holdings, may be deemed the beneficial owner of the (i) 6,376,738 Shares beneficially owned by Legion Partners I, (ii) 537,406 Shares beneficially owned by Legion Partners II, (iii) 200 Shares beneficially owned by Legion Partners Holdings and (iv) 77,575 Shares that were granted to Mr. Kiper by the Issuer in his capacity as a director of the Issuer. Percentage: Approximately 17.3% The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

Item 6

Contracts and arrangements

Item 6 is hereby amended to add the following: On September 27, 2026, the Reporting Persons, Parent and the Issuer entered into the Voting Agreement as defined and described in Item 4 above.

Item 7

Filed exhibits

Item 7 is hereby amended to add the following exhibit: 99.1 - Voting and Support Agreement, entered into as of September 27, 2026 (incorporated herein by reference to Exhibit 10.2 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026).

Signature 1

Reporting person
Legion Partners, L.P. I
Signed
/s/ Christopher S. Kiper
Title
Christopher S. Kiper, Managing Director of Legion Partners Asset Management, LLC, its Investment Advisor
Date
09/28/2026

Signature 2

Reporting person
Legion Partners, L.P. II
Signed
/s/ Christopher S. Kiper
Title
Christopher S. Kiper, Managing Director of Legion Partners Asset Management, LLC, its Investment Advisor
Date
09/28/2026

Signature 3

Reporting person
Legion Partners, LLC
Signed
/s/ Christopher S. Kiper
Title
Christopher S. Kiper, Managing Member of Legion Partners Holdings, LLC, its Managing Member
Date
09/28/2026

Signature 4

Reporting person
Legion Partners Asset Management, LLC
Signed
/s/ Christopher S. Kiper
Title
Christopher S. Kiper, Managing Director
Date
09/28/2026

Signature 5

Reporting person
Legion Partners Holdings, LLC
Signed
/s/ Christopher S. Kiper
Title
Christopher S. Kiper, Managing Member
Date
09/28/2026

Signature 6

Reporting person
Kiper Christopher S
Signed
/s/ Christopher S. Kiper
Title
Christopher S. Kiper
Date
09/28/2026

Signature 7

Reporting person
White Raymond T.
Signed
/s/ Raymond White
Title
Raymond White
Date
09/28/2026

Company context

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com. The contents of Lifecore’s website are not incorporated by reference into this press release.

Current securities

Recent company filings

  1. Entry into a Material Definitive AgreementSep 29, 2026
  2. DEFA14A filingSep 28, 2026
  3. Entry into a Material Definitive Agreement · Regulation FD DisclosureSep 28, 2026
  4. 10-Q filingAug 5, 2026
  5. Results of Operations and Financial Condition · Regulation FD DisclosureAug 5, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.